Ryan D Roberts

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Ryan D. Roberts

Biography

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Research

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Ryan D. Roberts

Biography

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Research

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Ryan D. Roberts

Contact Information

• Call us at:
• (614) 722-3550
• Fax us at:
• (614) 722-3369
• PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Ryan D. Roberts

Biography

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Biography

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Biography

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Ryan D. Roberts, MD, PhD, is a physician for the Division of Hematology and Oncology at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University.

Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children’s Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children’s Hospital, building on the research program that he developed as a resident and fellow.

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Hematology/Oncology & BMT

Physician Team

Center for Childhood Cancer

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

• Hematology/Oncology & BMT
• Physician Team
• Center for Childhood Cancer
• Principal Investigator
• Hematology, Oncology and BMT Fellowship
• Faculty
• Primary Department
• Pediatrics
• Primary Section
• Hematology & Oncology

Research

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal. Publications

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.

                


                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.

                


                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  

                


                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.

                


                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  

                


                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  

                


                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  

                


                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.

                


                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.

                


                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.

                


                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.

                


                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.

                


                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  

                


                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.

                


                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.

                


                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.

                


                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.

                


                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.

                


                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.

                


                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  

                


                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.

                


                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.

                


                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 

                


                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.

                


                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.

                


                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

View More Publications

Lab(s)

Center for Childhood Cancer

Dr. Roberts’ laboratory team seeks to understand the way that cancer cells co-opt the functions of normal cells as tumors grow and spread to distant parts of the body. Their initial work has focused on a specific bone cancer most common in adolescent and young adults called osteosarcoma. This cancer spreads with frustrating frequency from the bones to the lungs, where these metastases become quite difficult to treat, often proving fatal.

Lab(s)

Center for Childhood Cancer

• Center for Childhood Cancer

                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.
  
  
  
                  Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.
  
  
  
                  Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;  
  
  
  
                  Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.
  
  
  
                  Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;  
  
  
  
                  Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;  
  
  
  
                  Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;  
  
  
  
                  Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10;  20211088.
  
  
  
                  Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.
  
  
  
                  Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.
  
  
  
                  Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.
  
  
  
                  Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
  
  
  
                  Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;  
  
  
  
                  Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.
  
  
  
                  Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
  
  
  
                  Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.
  
  
  
                  Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.
  
  
  
                  Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.
  
  
  
                  Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
  
  
  
                  Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Jul 29;  
  
  
  
                  Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.
  
  
  
                  Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.
  
  
  
                  Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3: 
  
  
  
                  Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.
  
  
  
                  Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.
  
  
  
                  Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.
  
  

View More Publications

• Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8; 8: 77.
• Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Author Correction: Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 30; 8: 82.
• Soni UK, Wang Y, Pandey RN, Roberts R, Pressey JG, Hegde RS. Molecularly defined subsets of Ewing Sarcoma tumors differ in their responses to IGF1R and WEE1 inhibition. Clin Cancer Res. 2022 Nov 17;
• Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6: 65.
• Koo SC, Schieffer KM, Lee K, Gupta A, Pfau RB, Avenarius MR, Stonerock E, LaHaye S, Fitch J, Setty BA, Roberts R, Ranalli M, Conces MR, Bu F, Mardis ER, Cottrell CE. EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. Genes Chromosomes Cancer. 2022 Jul 7;
• Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2;
• Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 May 24;
• Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD. Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. Br J Radiol. 2022 Feb 10; 20211088.
• Khurshid S, Montes M, Comiskey DF Jr, Shane B, Matsa E, Jung F, Brown C, Bid HK, Wang R, Houghton PJ, Roberts R, Rigo F, Chandler D. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precis Oncol. 2022 Jan 11; 6: 1.
• Gupta A, Liu H, Schieffer KM, Koo SC, Cottrell CE, Mardis ER, Roberts RD, Yeager ND. Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion. J Natl Compr Canc Netw. 2021 Oct 15; 19: 1116-1121.
• Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children’s Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 Sep; 68: e29188.
• Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. iScience. 2021 Jul 23; 24: 102759.
• Avenarius MR, Miller CR, Arnold MA, Koo S, Roberts R, Hobby M, Grossman T, Moyer Y, Wilson RK, Mardis ER, Gastier-Foster JM, Pfau R. Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. J Mol Diagn. 2020 Aug 1;
• Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun 1; 126: 2577-2587.
• Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Int J Cancer. 2020 Jun 1; 146: 3184-3195.
• Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O’Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther. 2020 Mar; 19: 731-741.
• Reinecke JB, Roberts RD. Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma. Adv Exp Med Biol. 2020; 1258: 111-123.
• Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol. 2020; 10: 13.
• Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Immunotherapeutic Challenges for Pediatric Cancers. Mol Ther Oncolytics. 2019 Dec 20; 15: 38-48.
• Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children’s Oncology Group. Cancer. 2019 Jul 29;
• Patel P, Roberts R, Cole J, Stalling M, Nicol K, Hor K, Bowman J, Setty B. A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant. J Pediatr Hematol Oncol. 2019 May; 41: e206-e209.
• Roberts RD. Is Estrogen the Answer for Osteosarcoma? Cancer Res. 2019 Mar 15; 79: 1034-1035.
• Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018 Aug 23; 3:
• Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018; 8: 4.
• Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017 Oct 10; 8: 82037-82048.
• Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12: e0181885.

Education

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Education

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Education

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

Date of Appointment at Nationwide Children’s Hospital: 07/01/2016

Board Certifications

Pediatric Hematology Oncology Pediatrics

Fellowship

Nationwide Children’s Hospital

Date Completed: 06/30/2016

Residency

Nationwide Children’s Hospital

Date Completed: 06/30/2013

Medical School

Ohio State University College of Medicine

Date Completed: 06/13/2010

• Pediatric Hematology Oncology
• Pediatrics

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

• Call us at:
• (614) 722-3550
• Fax us at:
• (614) 722-3369
• Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)